In a significant move to bridge the persistent gap in women’s preventive healthcare, Everlywell has announced a strategic partnership with Waters Corporation. This collaboration introduces a robust, at-home cervical cancer screening solution centered on the BD Onclarity HPV Assay. By decentralizing the screening process, the partnership aims to overcome the traditional barriers of in-person clinical visits, providing a streamlined, accessible pathway for individuals to manage their cervical health from the comfort and privacy of their own homes.
The Core Partnership: Redefining Cervical Cancer Screening
The collaboration leverages Everlywell’s digital health infrastructure alongside the clinical precision of the BD Onclarity HPV Assay. The centerpiece of this initiative is the Onclarity HPV Self-Collection Kit. This kit is designed to meet the rigorous standards of modern diagnostics, providing patients with a reliable, FDA-cleared mechanism to screen for high-risk human papillomavirus (HPV) genotypes—the primary cause of cervical cancer.
For health plans, this partnership represents a transformative tool. Many members—particularly those in underserved communities or those with significant time constraints—often fall behind on recommended cervical cancer screenings. By integrating the self-collection kit into the care continuum, health plans can proactively reach these members, encouraging participation in a way that minimizes the "friction" associated with scheduling, traveling to, and waiting for an in-person appointment at a gynecological clinic.
Technical Precision: The BD Onclarity HPV Assay
At the heart of the diagnostic process is the BD Onclarity HPV Assay. Unlike generic screenings that may only provide a binary "positive/negative" result, the Onclarity system offers a more granular perspective. The assay is capable of detecting 14 high-risk HPV genotypes. Specifically, it identifies six individual genotypes and three groups of pooled results.
This level of detail is medically significant. By identifying specific genotypes, clinicians can better stratify risk, allowing for more tailored follow-up care. The samples, once collected at home by the user, are shipped directly to a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, ensuring that the results meet the same gold-standard accuracy as tests performed in a hospital setting.
Chronology: Navigating the Regulatory and Preventive Landscape
The timing of this launch is not coincidental. It follows a series of critical shifts in public health policy and diagnostic innovation:
- The Rise of Telehealth (2020–2024): The COVID-19 pandemic accelerated the adoption of at-home testing and virtual care. Everlywell emerged as a leader in this space, refining the logistics of direct-to-consumer testing.
- NCQA Measurement Year 2026 (MY2026): The National Committee for Quality Assurance (NCQA) introduced updated measures that place a higher premium on cervical cancer screening through electronic clinical data systems (CCS-E). The industry was suddenly tasked with improving screening rates despite the historical reliance on in-person visits.
- The 2027 Horizon: Federal preventive-services guidance is set to undergo further updates in 2027. The Everlywell and Waters Corporation partnership was strategically engineered to help health plans address current CCS-E care gaps before these new, more stringent regulations come into effect.
- Implementation (Q3 2026): With the announcement of the partnership in September 2026, the service is now positioned to roll out to health plans looking to boost their quality metrics and improve member health outcomes.
Official Responses and Strategic Vision
Julia Cheek, founder and CEO of Everlywell, highlighted the moral and practical imperatives driving this partnership. "Every woman deserves a clear and accessible path to understand her health and take the next right step," Cheek stated.
Her vision for the partnership extends beyond simple test distribution. She emphasizes a holistic approach to care: "By bringing together outreach, convenient screening access, clinician-guided results, and connected care systems, we can help plans close care gaps while preparing for the next generation of women’s preventive care."
The "connected care" aspect is crucial. The Everlywell platform does not simply drop a result into a patient’s inbox. Instead, it provides a structured ecosystem where members receive their results, gain access to telehealth consultations for clinical follow-up, and, if the result is abnormal, receive a seamless referral for in-person assessment. This ensures that the diagnostic process is not a "dead end" but a gateway to necessary medical intervention.
Implications for Public Health and Health Plans
The implications of this partnership are multifaceted, touching on economic, clinical, and social dimensions.
1. Closing the "Care Gap"
Traditional cervical cancer screening requires a pelvic exam, which can be an intimidating or inconvenient experience for many. By providing an alternative, health plans are likely to see a measurable increase in "screening compliance." This is vital for NCQA reporting, as health plans are often judged on the percentage of their population that is up-to-date on cancer screenings.
2. Early Detection and Risk Stratification
Because the BD Onclarity HPV Assay identifies specific genotypes, it facilitates more precise risk stratification. If a patient tests positive for a high-risk genotype, the referral process can be prioritized based on the specific strain detected. This optimizes clinical resources, ensuring that those at the highest risk receive prompt attention while reducing unnecessary anxiety for those with lower-risk results.
3. Future-Proofing for 2027
With the impending 2027 federal guidance updates, health plans that adopt these digital-first screening strategies will be better positioned to comply with evolving preventive care mandates. The ability to integrate at-home results directly into electronic health records (EHRs) via the Everlywell platform allows health plans to maintain accurate, up-to-date documentation of their members’ health status without the lag time associated with manual data entry from physical offices.
The Broader Ecosystem: Beyond HPV
It is important to view this partnership in the context of Everlywell’s broader diagnostic portfolio. The company has spent years building a comprehensive testing infrastructure that includes:
- Cardiometabolic Health: Monitoring blood pressure, cholesterol, and related biomarkers.
- Fertility and Hormones: Providing essential data for reproductive health planning.
- Sexual Health: Offering discreet, at-home STI screenings.
- Thyroid Function: Assisting in the management of endocrine health.
By adding the BD Onclarity HPV Assay to this menu, Everlywell is reinforcing its role as a "one-stop-shop" for preventive screening. This ecosystem approach is essential for modern health plans that want to incentivize members to take ownership of their health. When a member is already using a platform for fertility or general sexual health tracking, the introduction of a cervical cancer screening kit feels like a natural, logical extension of their existing care routine.
Addressing Barriers to Entry
The primary hurdle for home-based screening has historically been clinical trust. Can a patient collect a sample as effectively as a medical professional? The partnership addresses this by using the FDA-cleared Onclarity protocols, which have been specifically validated for patient-led collection. By ensuring that the lab processing the samples is CLIA-certified, the partnership bridges the trust gap, reassuring both patients and primary care physicians that the data is clinically actionable.
Conclusion: A New Standard for Preventive Medicine
The partnership between Everlywell and Waters Corporation represents a pivot point in how the US healthcare system approaches women’s preventive services. By moving away from a model that relies exclusively on physical clinical presence, and toward one that leverages technology to meet patients where they are, this initiative promises to save lives through earlier detection and higher screening participation rates.
As we move toward 2027, the success of this program will likely be measured not just by the number of kits distributed, but by the number of care gaps closed and the efficacy of the follow-up pathways established. If successful, this model could serve as a blueprint for the future of chronic disease screening, where the convenience of the home meets the precision of the laboratory, creating a more responsive and equitable healthcare system for all.
About the Author
